Centre prohibits selling Coronil as COVID-19 cure

▴ centre-prohibits-selling-coronil-covid19-cure
Ayush ministry has only given the approval to sell this specific formulation as an immunity booster and not as a medicinal remedy for COVID-19.

The Union ministry has banned Patanjali from selling Coronil as a cure for COVID-19.

Ayush ministry has only given the approval to sell this specific formulation as an immunity booster and not as a medicinal remedy for COVID-19, it said.  At a press conference in Haridwar, Ramdev insisted the ministry has said that Patanjali did an appropriate job for COVID-19 management.

 However, on Wednesday Yoga guru Ramdev's Patanjali Ayurved stated that there are no Ayush ministry constraints on selling 'Coronil', a drug the company recently inaugurated as medicine for COVID-19 but is now calling it a product to regulate the disease.

"I want to tell people who want to try these medicines that there is no restriction on their sale now and they will be available in a kit everywhere in the country from today," he added, citing Coronil and the two other products Patanjali is promoting together.

Ramdev told the Union ministry had asked him to use the term 'COVID-19 management' in place of 'COVID-19 treatment' and he is obeying the instruction.

Even while backtracking on characterizing Coronil as a treatment for COVID-19, the company stuck to its statement that the drug's examination on mild to moderately ill patients was successful.

Its press note said the examination, conducted after the necessary permissions, showed 100 percent recovery of patients under seven days.

It started that the Ayush ministry has categorically decided that Patanjali had suitably worked on COVID-19 management.

Now there is no disparity of opinion between Ayush ministry and Patanjali, it added.

According to the ministry, Patanjali is authorized to manufacture and dispense its Diva Coronil tablet, Divya Swasari Vati and Divya Anu Talia across India, as per the manufacturing licences awarded by State Licensing Authority, Ayurvedic and Unani Services, Govt of Uttarakhand, it said.

The Uttarakhand department was among the agencies which had challenged Patanjali's claim to have formulated a drug to cure COVID-19. It said the company had only been given a license to produce an immunity booster

Tags : #Coronil #Patanjali #COVID-19

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Breaking Barriers: Honouring the International Day of Persons with Disabilities December 03, 2024
Invisible Threat: How Air Pollution is Impacting Pregnancies and Shaping Future GenerationsDecember 03, 2024
Medanta Gurugram successfully treats ‘rarest of rare’ lymph node cancer resistant to other drugs using CAR-T Cell TherapyDecember 03, 2024
Nonin Medical secures FDA clearance for its over-the-counter fingertip pulse oximeter, accurate for patients of all skin colorsDecember 02, 2024
ALARM 2024: Amrita Leads the Fight Against Antimicrobial ResistanceDecember 02, 2024
Coral adaptation unlikely to keep pace with global warmingDecember 02, 2024
Reaching the unreached to find missing TB casesDecember 02, 2024
Sip Smart: Why Changing Your Water Habits Can Change Your LifeNovember 28, 2024
Can Your Fingers Predict How Much You Drink? New Study ExplainsNovember 28, 2024
India Leads Global Medical Tourism with 8% Share; PSRI Sets New Benchmarks with nearly 15% International Patient BaseNovember 28, 2024
Medicines save lives but not when they stop workingNovember 28, 2024
A total of 340 Children Participated in the Painting Competition Organized by Asian HospitalNovember 28, 2024
The Standing Desk Myth: Is Sitting Actually Healthier?November 27, 2024
How Cancer Outsmarts Chemotherapy: The Hidden Metabolic GameNovember 27, 2024
Aakash Healthcare Saves life of a 61-year-old Women through Timely Neuro-intervention with a multi-disciplinary management of StrokeNovember 27, 2024
Breakfast Wars: Why Men and Women Should Eat DifferentlyNovember 27, 2024
Only 10% of Businesses Are Ready to Become Experience-Orchestrated, Highlighting Lack of PersonalisationNovember 27, 2024
Investors Think Safe, but Act Bold: MyFi Report Exposes Risk Tolerance Mismatch November 27, 2024
Indkal Technologies Redefines Luxury Home Entertainment with Acer M Series Hybrid MiniLED TelevisionsNovember 27, 2024
Fat’s Double-Edged Sword: How It Protects and Betrays Your HealthNovember 27, 2024